Table 1.
Baseline and treatment characteristics for all patients included in the analysis.
| Mean age at diagnosis (SD) | 57 (9) | |
| Male Sex, N (%) | 163 (60) | |
| Cytogenetic risk, N (%) | Standard High N/A |
146 (53) 39 (14) 88 (32) |
| ISS stage, N (%) | Stage I Stage II Stage III N/A |
93 (34) 72 (26) 46 (17) 57 (21) |
| LDH, Mean (SD) | 175 (70) | |
| Monoclonal component, N (%) |
IgG IgA IgM FLC only |
154 (56) 51 (19) 2 (1) 66 (24) |
| Kappa/Lambda ratio, N (%) | Normal Abnormal N/A |
17(6) 199 (73) 57 (21) |
| Mean time from diagnosis to transplantation, months (SD) |
11 (10) | |
| Mean time from initial treatment to transplantation, months (SD) |
8 (4) | |
| *Induction agents | Thalidomide Lenalidomide Bortezomib Other |
128 58 74 70 |
| Maintenance agents | Thalidomide Lenalidomide Interferon Cyclophosphamide None |
22 33 2 1 215 |
| Type of transplant, N (%) | Single auto Tandem auto-auto |
235 (86) 38 (14) |
| Best response after transplantation (IMWG), N (%) |
CR nCR VGPR PR SD POD |
146 (53) 39 (14) 41 (15) 33 (12) 1 (0.3) 3 (1) |
*
Agents overlapped in some regimens